Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.40 |
| ▸ | RELA | Q04206 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638573 | 0.83 | RAB9A (0.63) | SMN1; SMN2MAPTTP53DYRK1ATDP1 | |
| SCHEMBL92781 | 0.81 | SMN1; SMN2 (0.61) | SMN1; SMN2MAPTTP53DYRK1ATDP1 | |
| Bromide SCHEMBL10996884 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2MAPTTP53DYRK1ATDP1 | |
| SCHEMBL17836733 | 0.78 | DYRK1A (0.53) | MAPTDYRK1ARAB9ACYP1A2NPC1 | |
| SCHEMBL11549599 | 0.78 | DYRK1A (0.54) | SMN1; SMN2MAPTTP53DYRK1ATDP1 | |
| SCHEMBL12262 | 0.78 | MAPT (0.72) | SMN1; SMN2MAPTTP53DYRK1ARAB9A | |
| SCHEMBL2749398 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTTP53DYRK1ATDP1 | |
| SCHEMBL799569 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTTP53DYRK1ATDP1 | |
| SCHEMBL29572251 | 0.78 | MAPT (0.72) | SMN1; SMN2MAPTTP53DYRK1ARAB9A | |
| SCHEMBL30189802 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPTTP53DYRK1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | CHECKMATE THERAPEUTICS INC. (KR) | 2026-01-22 | — | — | US | disclosed |
| WO-2023229346-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | 주식회사 체크메이트테라퓨틱스 | 2023-11-30 | — | — | WO | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | FORUM PHARMACEUTICALS, INC. | 2017-08-31 | — | — | US | disclosed |
| WO-2017069980-A1 | AMINOISOXAZOLINE COMPOUNDS AS AGONISTS OF ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTORS | FORUM PHARMACEUTICALS, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-9296738-B2 | Organic electroluminescent material, the process for preparing the same and OLED device using the same | EVERDISPLAY OPTRONICS (SHANGHAI) LIMITED (CN) | 2016-03-29 | — | — | US | disclosed |
| US-9296738-B2 | Organic electroluminescent material, the process for preparing the same and OLED device using the same | EVERDISPLAY OPTRONICS (SHANGHAI) LIMITED (CN) | 2016-03-29 | — | — | US | disclosed |
| US-9296738-B2 | Organic electroluminescent material, the process for preparing the same and OLED device using the same | EVERDISPLAY OPTRONICS (SHANGHAI) LIMITED (CN) | 2016-03-29 | — | — | US | disclosed |
| CN-103756670-B | Electroluminescent organic material and its preparation method and application | SHANGHAI HEHUI PHOTOELECTRICITY CO., LTD. (CN) | 2015-12-09 | — | — | CN | disclosed |
| US-20150203485-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, THE PROCESS FOR PREPARING THE SAME AND OLED DEVICE USING THE SAME | EVERDISPLAY OPTRONICS (SHANGHAI) CO., LTD. (CN) | 2015-07-23 | — | — | US | disclosed |
| US-20150203485-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, THE PROCESS FOR PREPARING THE SAME AND OLED DEVICE USING THE SAME | EVERDISPLAY OPTRONICS (SHANGHAI) CO., LTD. (CN) | 2015-07-23 | — | — | US | disclosed |
| US-20150203485-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, THE PROCESS FOR PREPARING THE SAME AND OLED DEVICE USING THE SAME | EVERDISPLAY OPTRONICS (SHANGHAI) CO., LTD. (CN) | 2015-07-23 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| CN-103756670-A | Organic electroluminescence material as well as preparation method and application thereof | SHANGHAI EVERDISPLAY OPTRONICS CO LTD | 2014-04-30 | — | — | CN | disclosed |
| US-5347008-A | Thio(cyclo) alkanepolycarboxylic acids containing heterocyclic substituents | CIBA-GEIGY CORPORATION (US) | 1994-09-13 | — | — | US | disclosed |
| US-5152929-A | Corrosion inhibitors for water systems | CIBA-GEIGY CORPORATION (US) | 1992-10-06 | — | — | US | disclosed |
| EP-0129506-B1 | HETEROCYCLICALLY SUBSTITUTED THIO(CYCLO)ALKANE POLYCARBOXYLIC ACIDS | CIBA-GEIGY AG (CH) | 1991-03-06 | — | — | EP | disclosed |
| EP-0129506-A2 | Heterocyclically substituted thio(cyclo)alkane polycarboxylic acids | CIBA-GEIGY AG (CH) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247393-A1 | Aminoisoxazoline Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors | CHRNA7, CHRNA5, CHRNA2 | SMN1; SMN2 696/4885MAPT 1038/4885TP53 4122/4885 |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | SMN1; SMN2 3594/4885MAPT 2725/4885TP53 2041/4885 |
| US-20150203485-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL, THE PROCESS FOR PREPARING THE SAME AND OLED DEVICE USING THE SAME | OCIAD1, OCIAD2, OR10J3 | SMN1; SMN2 3556/4885MAPT 3498/4885TP53 4399/4885 |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | SMN1; SMN2 4772/4885MAPT 4784/4885TP53 4879/4885 |
| US-20260022122-A1 | NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME | NAMPT, NAPRT, NNT | SMN1; SMN2 2571/4885MAPT 1402/4885TP53 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.